6-氯-2,3,4,5-四氢-1H-苯并[D]氮杂卓 | 26232-35-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 6-氯-2,3,4,5-四氢-1H-苯并[D]氮杂卓
• 英文名称: 6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine
• 英文别名: 6-Chlor-2,3,4,5-tetrahydro-1H-3-benzazepin；6-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine
• CAS: 26232-35-9
• 化学式: C₁₀H₁₂ClN
• 分子量: 181.665
• InChiKey: KGJFKHNSLOSGMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-氯-2,3,4,5-四氢-1H-苯并[D]氮杂卓 在 吡啶 、 乙酸酐 作用下， 生成 3-acetyl-6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine
  参考文献：
  名称：

  Pharmaceutical compositions and methods for producing alpha antagonism

  摘要：

  制药组合物和制备α2拮抗剂的方法使用6-卤代-N-取代的2,3,4,5-四氢-1H-3-苯并哌啶作为活性成分。这些组合物特别适用于降低眼压和治疗异常心血管疾病，例如充血性心力衰竭、心绞痛和血栓形成。此发明的组合物和化合物还可降低高血压患者的血压，因此可用作降压剂。

  公开号：

  US04496558A1
• 作为产物：
  描述：

  6-chloro-3-cyano-2,3,4,5-tetrahydro-1H-3-benzazepine 生成 6-氯-2,3,4,5-四氢-1H-苯并[D]氮杂卓
  参考文献：
  名称：

  DEMARINIS, R. M.;HIEBLE, J. P.;MATTHEWS, W. D.

  摘要：

  DOI：

文献信息

• Benzazepine Compound
  申请人：KOSHIO Hiroyuki

  公开号：US20110269744A1

  公开（公告）日：2011-11-03

  [Problem] Provided is a compound which is useful as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. [Means for Solution] The present inventors have investigated compounds having a 5-HT 2C receptor agonist activity, which is promising as an active ingredient of a pharmaceutical composition for treating or preventing incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like, and have found that the benzazepine compounds of the present invention have an excellent 5-HT 2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT 2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

  提供的是一种化合物，可用作治疗或预防与5-HT 2C 受体相关的疾病的药剂，特别是尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等。 【解决方案】本发明者研究了具有5-HT 2C 受体激动剂活性的化合物，这种活性有望作为治疗或预防尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等的药物组合物的有效成分。他们发现本发明的苯并环己酮类化合物具有出色的5-HT 2C 受体激动剂活性，从而完成了本发明。换句话说，本发明的苯并环己酮类化合物具有5-HT 2C 受体激动剂活性，可用作治疗或预防与5-HT 2C 受体相关的疾病的药剂，特别是尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等。
• Development of an affinity ligand for purification of .alpha.2-adrenoceptors from human platelet membranes
  作者：R. M. DeMarinis、A. J. Krog、D. H. Shah、J. Lafferty、K. G. Holden、J. P. Hieble、W. D. Matthews、J. W. Regan、R. J. Lefkowitz、M. G. Caron

  DOI：10.1021/jm00373a018

  日期：1984.7

  prepared as affinity ligands for this purpose. The best of these is 9-(allyloxy)-6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SK&F 101253). This compound is an alpha 2-adrenoceptor antagonist, which was obtained by synthetic modification of 6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SK&F 86466), a novel antagonist with high affinity for the alpha 2-receptor.

  人血小板含有与腺苷酸环化酶负偶联的α2-肾上腺素能受体。为了更好地了解这种α受体亚型与这种关键酶的相互作用，我们启动了一个程序来分离和表征α2-肾上腺素能受体。该报告描述了为此目的制备为亲和配体的一系列分子的合成和生物学特性。其中最好的是9-（烯丙氧基）-6-氯-3-甲基-2,3,4,5-四氢-1H-3-苯并ze庚因（SK＆F 101253）。该化合物是α2肾上腺素能受体拮抗剂，是通过对6-氯-3-甲基-2,3,4,5-四氢-1H-3-苯并ze庚因（SK＆F 86466）进行合成修饰而获得的，SK-F 86466对α2受体的亲和力。
• BENZAZEPINE COMPOUND
  申请人：Koshio Hiroyuki

  公开号：US20130012496A1

  公开（公告）日：2013-01-10

  Provided is a compound which is useful as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT 2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT 2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT 2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

  提供了一种化合物，可用作治疗或预防5-HT2C受体相关疾病的药剂，特别是尿失禁，如压力性尿失禁，切勿性尿失禁，混合性尿失禁等，性功能障碍，如勃起功能障碍综合症等，肥胖症等。本发明人研究了具有5-HT2C受体激动剂活性的化合物，并发现本发明的苯并氮杂环化合物具有优异的5-HT2C受体激动剂活性，从而完成了本发明。也就是说，本发明的苯并氮杂环化合物具有5-HT2C受体激动剂活性，并可用作治疗或预防5-HT2C受体相关疾病的药剂，特别是尿失禁，如压力性尿失禁，切勿性尿失禁，混合性尿失禁等，性功能障碍，如勃起功能障碍综合症等，肥胖症等。
• 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0080012A1

  公开（公告）日：1983-06-01

  6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate to prepare mercapto substituted-2,3,4,5-tetrahydro-1H-3- benzazepines as disclosed in European Patent Application No. 79102279.1.

  欧洲专利申请 79102279.1 号中公开的 6-氯-3-甲基-2,3,4,5-四氢-1H-3-苯并氮杂卓、其酸加成盐及其作为中间体制备巯基取代的-2,3,4,5-四氢-1H-3-苯并氮杂卓的用途。
• 3-Benzazepines as alpha-2 antagonists
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0080779A1

  公开（公告）日：1983-06-08

  A pharmaceutical composition for producing alpha2 antagonism comprising a pharmaceutically acceptable carrier and a 3-benzazepine compound of the formula: in which R is a lower alkyl having from 1 to 3 carbon atoms or allyl; and X is halogen; or a pharmaceutically acceptable acid addition salt thereof.

  一种用于产生α2 拮抗作用的药物组合物，包括一种药学上可接受的载体和一种式 3-苯并氮杂卓化合物： 其中 R 是具有 1 至 3 个碳原子的低级烷基或烯丙基；以及 X为卤素；或其药学上可接受的酸加成盐。